PE20080124A1 - AEROSOL FORMULATIONS CONTAINING S-FLUOROMETHYL ESTER OF 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA [(2-FURANYLCARBONYL) OXY] -11BETA-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROSTE, 1,4-DIENO-CARBONYL - Google Patents

AEROSOL FORMULATIONS CONTAINING S-FLUOROMETHYL ESTER OF 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA [(2-FURANYLCARBONYL) OXY] -11BETA-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROSTE, 1,4-DIENO-CARBONYL

Info

Publication number
PE20080124A1
PE20080124A1 PE2007000310A PE2007000310A PE20080124A1 PE 20080124 A1 PE20080124 A1 PE 20080124A1 PE 2007000310 A PE2007000310 A PE 2007000310A PE 2007000310 A PE2007000310 A PE 2007000310A PE 20080124 A1 PE20080124 A1 PE 20080124A1
Authority
PE
Peru
Prior art keywords
androste
9alpha
6alpha
dieno
17alpha
Prior art date
Application number
PE2007000310A
Other languages
Spanish (es)
Inventor
John Capecchi
James Stefely
Trevor Riley
Original Assignee
Glaxo Group Ltd
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38523271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080124(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd, 3M Innovative Properties Co filed Critical Glaxo Group Ltd
Publication of PE20080124A1 publication Critical patent/PE20080124A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA EN AEROSOL QUE CONTIENE: A) UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE ESTER S-FLUOROMETILICO DE 6ALFA,9ALFA-DIFLUORO-17ALFA[(2-FURANILCARBONIL)OXI]-11BETA-HIDROXI-16ALFA-METIL-3-OXO-ANDROSTA,1,4-DIENO-17BETA-CARBOTIOICO; B) UN PROPULSOR SELECCIONADO DEL GRUPO QUE CONSISTE EN 1,1,2,- TETRAFLUOROETANO ò 1,1,1,2,3,3,3-HEPTAFLUORO-n-PROPANO O UNA MEZCLA DE ESTOS; C) UN POLIMERO BIOCOMPATIBLE EN UN RANGO DE 0.05%-0.2% CON RELACION AL PROPULSOR QUE COMPRENDE UNO MAS COMPUESTOS DE FOMULA (II) DONDE n y m ES UN NUMERO ENTERO DE AL MENOS 1 Y EL VALOR PROMEDIO INDEPENDIENTE DE n y m EN EL POLIMERO BIOCOMPATIBLE ESTA ENTRE 6 y 25. DICHA FORMULACION COMPRENDE ADEMAS UN AGENTE ACTIVO ADICIONAL SELECCIONADO DE SALMETEROL, (R)-SALMETEROL, SALBUTAMOL, TERBUTALINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA FORMULACION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LAS FORMULACIONES DESCRITAS SON UTILES EN EL TRATAMIENTO DE ASMA BROQUIAL, ENFERMEDAD OBSTRUCTIVA PULMONAR CRONICA, Y RELACIONADASREFERS TO A PHARMACEUTICAL FORMULATION IN AEROSOL CONTAINING: A) A THERAPEUTICALLY EFFECTIVE AMOUNT OF 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA [(2-FURANYLCARBONYL) -OXYPHAOXYL-3-HYDROXYL-3-HYDROXYL-3-HYDROXYL-ESTER -ANDROSTE, 1,4-DIENO-17BETA-CARBTIOICO; B) A PROPELLER SELECTED FROM THE GROUP CONSISTING OF 1,1,2, - TETRAFLUOROETHANE ò 1,1,1,2,3,3,3-HEPTAFLUORO-n-PROPANE OR A MIXTURE OF THESE; C) A BIOCOMPATIBLE POLYMER IN A RANGE OF 0.05% -0.2% RELATED TO THE PROPELLER THAT INCLUDES ONE MORE COMPOUNDS OF FORMULA (II) WHERE n and m IS AN INTEGRAL NUMBER OF AT LEAST 1 AND THE INDEPENDENT AVERAGE VALUE OF n and m IN THE BIOTACOMPATIOUS POLYMER IS BETWEEN 6 and 25. SUCH FORMULATION ALSO INCLUDES A SELECTED ADDITIONAL ACTIVE AGENT OF SALMETEROL, (R) -SALMETEROL, SALBUTAMOL, TERBUTALINE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL FORMULATION AND A PREPARATION PROCEDURE. THE DESCRIBED FORMULATIONS ARE USEFUL IN THE TREATMENT OF BROCHIAL ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND RELATED

PE2007000310A 2006-03-22 2007-03-21 AEROSOL FORMULATIONS CONTAINING S-FLUOROMETHYL ESTER OF 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA [(2-FURANYLCARBONYL) OXY] -11BETA-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROSTE, 1,4-DIENO-CARBONYL PE20080124A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78463406P 2006-03-22 2006-03-22

Publications (1)

Publication Number Publication Date
PE20080124A1 true PE20080124A1 (en) 2008-04-21

Family

ID=38523271

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000310A PE20080124A1 (en) 2006-03-22 2007-03-21 AEROSOL FORMULATIONS CONTAINING S-FLUOROMETHYL ESTER OF 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA [(2-FURANYLCARBONYL) OXY] -11BETA-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROSTE, 1,4-DIENO-CARBONYL

Country Status (18)

Country Link
EP (1) EP2012797A2 (en)
JP (1) JP2009530419A (en)
KR (1) KR20080110854A (en)
CN (1) CN101415428A (en)
AR (1) AR060039A1 (en)
AU (1) AU2007226899A1 (en)
BR (1) BRPI0708798A2 (en)
CA (1) CA2646236A1 (en)
CR (1) CR10261A (en)
EA (1) EA200801854A1 (en)
IL (1) IL193723A0 (en)
MA (1) MA30328B1 (en)
MX (1) MX2008011967A (en)
NO (1) NO20083760L (en)
PE (1) PE20080124A1 (en)
TW (1) TW200803870A (en)
WO (1) WO2007109698A2 (en)
ZA (1) ZA200807682B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689424B1 (en) * 1993-03-17 1998-10-14 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
AR032361A1 (en) * 2000-08-05 2003-11-05 Glaxo Group Ltd DERIVATIVES OF ANDROSTAN AND SALTS AND SOLVATOS OF THE SAME, ITS USE FOR THE MANUFACTURE OF MEDICINES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS, PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS, AND USEFUL INTERMEDIARIES IN THE PREPARATION OF SUCH COMPOUNDS
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative

Also Published As

Publication number Publication date
KR20080110854A (en) 2008-12-19
NO20083760L (en) 2008-12-17
MA30328B1 (en) 2009-04-01
EA200801854A1 (en) 2009-04-28
CA2646236A1 (en) 2007-09-27
JP2009530419A (en) 2009-08-27
IL193723A0 (en) 2009-08-03
EP2012797A2 (en) 2009-01-14
ZA200807682B (en) 2009-11-25
WO2007109698A3 (en) 2008-12-18
AU2007226899A1 (en) 2007-09-27
CR10261A (en) 2008-11-26
MX2008011967A (en) 2009-01-14
AR060039A1 (en) 2008-05-21
TW200803870A (en) 2008-01-16
CN101415428A (en) 2009-04-22
WO2007109698A2 (en) 2007-09-27
BRPI0708798A2 (en) 2011-06-14

Similar Documents

Publication Publication Date Title
WO2021102411A8 (en) Ionizable lipids and nanoparticle compositions thereof
US9050293B2 (en) Small molecule solubilization system
JP2007530573A5 (en)
CA2359812A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
ECSP088239A (en) COMPOSITION OF SUSTAINED DRUG RELEASE
CL2007003356A1 (en) COMPOUNDS DERIVED FROM BENZOPIRAZOLES; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE FOR THE TREATMENT OF ASTHMA, INFLAMMATION, AMONG OTHER DISEASES.
BRPI0608690A2 (en) use of an antimicrobial composition
MX2012006720A (en) Pharmaceutical composition for treatment of dry eye syndrome.
EA200802444A1 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING PHESTERODINE
RS52940B (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
WO2007084247A3 (en) Stable therapeutic formulations
DE602006004451D1 (en) MUCOADHESIVE XYLOGLUCAN-CONTAINING FORMULATION FOR MEDICAL PRODUCTS AND PHARMACEUTICAL PHARMACEUTICAL FORMS
AU6947801A (en) Hyaluronic acid oligosaccharide fractions and drugs containing the same
ECSP088653A (en) PHARMACEUTICAL FORMULATION FOR AEROSOLS WITH TWO OR MORE ACTIVE PRINCIPLES AND AT LEAST A TENSOACTIVE SUBSTANCE
WO2005004917A3 (en) Pharmaceutical composition for solubility enhancement of hydrophobic drugs
PE20091949A1 (en) SOLID PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE
NZ602538A (en) Thermogelling anaesthetic compositions
DE102014009164A1 (en) Silicone oil containing nasal formulations
BRPI0915119B8 (en) use of carrageenan iota
ES2860098T3 (en) Composition for nasal application
WO2015081904A3 (en) Polyurethaneurea solutions for compositions with active ingredients or fragrances
PE20080124A1 (en) AEROSOL FORMULATIONS CONTAINING S-FLUOROMETHYL ESTER OF 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA [(2-FURANYLCARBONYL) OXY] -11BETA-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROSTE, 1,4-DIENO-CARBONYL
JP2008541745A5 (en)
BRPI0602397C1 (en) pharmaceutical compositions for the treatment of liver fat diseases, obesity and other diseases associated with the metabolic syndrome and methods of treatment using said compositions
BR112015013689A2 (en) peroxide containing oral care fluid compositions

Legal Events

Date Code Title Description
FD Application declared void or lapsed